References
- Shannon M. Ketamine induced false positive drug screen in a teen: unnecessary call to police and social services (letter). Ped Emerg Care 1998; 14: 180
- Sena S. F., Kazimi S., Wu A. H. False‐positive phencyclidine immunoassay results caused by venlafaxine and O‐desmethylvenlafaxine (letter). Clinical Chemistry 2002; 48(4)676–677
- Abbott AxSYM® system Phencyclidine II product insert. July, 1999, Abbott Laboratories
- Woo O. F., Vrendenber M., Feitas P., Olson K. R. Seizures after venlafaxine overdose: a case report (abstract). J Toxicol Clin Toxicol 1995; 33: 549–550
- Troy S. M., Parker V. D., Fruncillo R. J., Chaing S. T. The pharmacokinetics of venlafaxine when given in a twice‐daily regimen. J Clin Pharmacol 1995; 35: 404–409
- Sinegal M. September 19, 2002, Abbott Labotatories, Personal communication, phone call
- Youshock K., Pharm D. Manager, Global Product Information, Wyeth‐Ayerst Pharmaceuticals. April 23, 2001, Personal communication, letter
- Rainey P. M. Laboratory principles and techniques for the evaluation of the poisoned or overdosed patient. Goldfrank's Toxicologic Emergencies7th Ed., L. R. Goldfrank, N. E. Flomenbaum, N. A. Lewin, M. A. Howland, R. S. Hoffman, L. S. Nelson. McGraw Hill, New York 2002; 69–93
- Simone K., Bond G. R. Detection of unusual abuse patterns using broad searching of the toxic exposure surveillance system (abstract). J Toxicol Clin Toxicol 2002; 40: 657–658
- Simone K., Bond G. R. Dextromethorphan: a successful example of monitoring for emerging ause using the toxic exposure surveillance system (abstract). J Toxicol Clin Toxicol 2002; 40: 653–654